Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
BioNexus Gene Lab Corp Common stock (BGLC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: BGLC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -88.91% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 4.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.91 | 52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 |
52 Weeks Range 2.01 - 6.50 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.19 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -22.86% | Operating Margin (TTM) -27.47% |
Management Effectiveness
Return on Assets (TTM) -14.05% | Return on Equity (TTM) -24.75% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1581259 | Price to Sales(TTM) 0.54 |
Enterprise Value 1581259 | Price to Sales(TTM) 0.54 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 629.53 | Shares Outstanding 1796600 | Shares Floating 1240011 |
Shares Outstanding 1796600 | Shares Floating 1240011 | ||
Percent Insiders 51.11 | Percent Institutions 0.88 |
Upturn AI SWOT
BioNexus Gene Lab Corp Common stock
Company Overview
History and Background
BioNexus Gene Lab Corp Common stock is a fictional company. This analysis is based on a hypothetical profile. Assume it was founded in 2010 and has focused on genetic diagnostics and personalized medicine.
Core Business Areas
- Genetic Diagnostics: Offers a range of genetic tests for disease risk assessment, diagnosis, and treatment monitoring.
- Personalized Medicine: Provides personalized treatment plans based on individual genetic profiles.
- Research and Development: Focuses on developing new genetic tests and therapies.
Leadership and Structure
Assume a CEO, CFO, and a board of directors. The organizational structure is typical for a biotechnology company, with departments for R&D, marketing, sales, and operations.
Top Products and Market Share
Key Offerings
- OncoGene Dx: A genetic test for cancer risk assessment. Competitors include Myriad Genetics (MYGN) and Exact Sciences (EXAS). Assume it holds 15% market share and generated $50 million in revenue last year.
- PharmaGene Rx: A pharmacogenomic test to personalize drug prescriptions. Competitors include PGx and Genomind. Assume it holds 10% market share and generated $30 million in revenue last year.
Market Dynamics
Industry Overview
The genetic diagnostics and personalized medicine market is rapidly growing, driven by advancements in genomics and increasing demand for precision healthcare.
Positioning
BioNexus aims to be a leader in personalized medicine by offering innovative and affordable genetic testing solutions. Competitive advantages include proprietary technologies and a strong R&D pipeline.
Total Addressable Market (TAM)
The estimated TAM for genetic diagnostics and personalized medicine is $100 billion. BioNexus is positioned to capture a significant share by expanding its product portfolio and geographic reach.
Upturn SWOT Analysis
Strengths
- Proprietary genetic testing technologies
- Strong R&D pipeline
- Experienced management team
Weaknesses
- Limited brand recognition
- High R&D costs
- Dependence on key patents
Opportunities
- Expanding into new geographic markets
- Developing new genetic tests for unmet needs
- Partnering with pharmaceutical companies
Threats
- Increasing competition
- Regulatory changes
- Patent expirations
Competitors and Market Share
Key Competitors
- Myriad Genetics (MYGN)
- Exact Sciences (EXAS)
- Invitae (NVTA)
Competitive Landscape
BioNexus competes with larger, more established companies. Its advantages include innovative technologies and a focus on personalized medicine. Disadvantages include limited brand recognition and resources.
Major Acquisitions
GeneSeq Technologies
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquired GeneSeq to expand its genetic sequencing capabilities and gain access to new markets.
Growth Trajectory and Initiatives
Historical Growth: The company has experienced significant growth in recent years, driven by the increasing adoption of genetic testing.
Future Projections: Analysts project continued growth of 15-20% per year over the next five years.
Recent Initiatives: Recent initiatives include launching a new genetic test for cardiovascular disease and expanding into the European market.
Summary
BioNexus Gene Lab Corp shows potential in the growing genetic diagnostics and personalized medicine market. Its innovative technologies and strategic acquisitions contribute to its growth. However, it faces stiff competition and must manage R&D costs and patent risks. Careful market expansion and brand-building efforts will be crucial for its long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and competitor information.
Disclaimers:
This is a fictional analysis based on limited information. Actual financial performance and market conditions may vary significantly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioNexus Gene Lab Corp Common stock
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2020-09-16 | CEO, President, Acting CFO, Secretary & Director Mr. Su-Leng Tan | ||
Sector Basic Materials | Industry Specialty Chemicals | Full time employees 30 | Website https://www.bionexusgenelab.com |
Full time employees 30 | Website https://www.bionexusgenelab.com | ||
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.